These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 2965123)
21. Treatment of skin and soft tissue infections with cefadroxil, a new oral cephalosporin. Cordero A J Int Med Res; 1976; 4(3):176-8. PubMed ID: 1026545 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of intraventricular teicoplanin for the treatment of neurosurgical shunt infections. Cruciani M; Navarra A; Di Perri G; Andreoni M; Danzi MC; Concia E; Bassetti D Clin Infect Dis; 1992 Aug; 15(2):285-9. PubMed ID: 1387805 [TBL] [Abstract][Full Text] [Related]
23. Oritavancin for skin infections. Anderson DL Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268 [TBL] [Abstract][Full Text] [Related]
24. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. Van Laethem Y; Hermans P; De Wit S; Goosens H; Clumeck N J Antimicrob Chemother; 1988 Jan; 21 Suppl A():81-7. PubMed ID: 2965135 [TBL] [Abstract][Full Text] [Related]
25. Teicoplanin in the treatment of infection caused by gram-positive organisms. Williams AH; Grüneberg RN; Webster A; Ridgway GL J Hosp Infect; 1986 Mar; 7 Suppl A():101-3. PubMed ID: 2871091 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of teicoplanin in infections caused by methicillin-resistant Staphylococcus aureus. Pachon J; Prados D; Palomino J; Cantos A; Cisneros JM; Vaquero F J Antimicrob Chemother; 1996 Jan; 37(1):197-200. PubMed ID: 8647768 [No Abstract] [Full Text] [Related]
33. An outbreak of group A streptococcal skin infection: control by source isolation and teicoplanin therapy. Webster A; Scott GM; Ridgway GL; Grüneberg RN Scand J Infect Dis; 1987; 19(2):205-9. PubMed ID: 2956671 [TBL] [Abstract][Full Text] [Related]
34. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Van der Auwera P; Aoun M; Meunier F Antimicrob Agents Chemother; 1991 Mar; 35(3):451-7. PubMed ID: 1828134 [TBL] [Abstract][Full Text] [Related]
35. [Efficacy and tolerance of teicoplanin in postoperative infections caused by gram-positive microorganisms]. Alberghina A; Romeo B; Pessione E; Mauri A; Enrichens F; Sciascia C; Olivero G Minerva Chir; 1987 Sep; 42(17):1339-45. PubMed ID: 2959879 [No Abstract] [Full Text] [Related]
36. Infections due to gram-positive organisms in children: possible role for teicoplanin. Dagan R; Einhorn M; Howard CB; Williams AH J Antimicrob Chemother; 1991 Apr; 27 Suppl B():37-41. PubMed ID: 1829075 [TBL] [Abstract][Full Text] [Related]
37. Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin. Greenberg RN Antimicrob Agents Chemother; 1990 Dec; 34(12):2392-7. PubMed ID: 2150908 [TBL] [Abstract][Full Text] [Related]
38. [Teicoplanin in otorhinolaryngology]. Cavallo GP; Malcangi A G Batteriol Virol Immunol; 1986; 79(7-12):250-7. PubMed ID: 2969345 [TBL] [Abstract][Full Text] [Related]
39. The international experience with teicoplanin in the treatment of skin and soft tissue infections. Chiodo F; Verucchi G; Acuto G J Chemother; 1989 Jul; 1(4 Suppl):712-3. PubMed ID: 16312603 [No Abstract] [Full Text] [Related]